Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy

International Ophthalmology

Volumn 37, Issue 5, 2017, Pages 1115-1125

  Pichi, Francesco ^a,b   Carrai, Paola ^b   Ciardella, Antonio ^c   Behar Cohen, Francine ^d   Nucci, Paolo ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b University Clinic   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Central serous chorioretinopathy; Eplerenone; Mineralocorticoid; Spironolactone

Indexed keywords

EPLERENONE; PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL SEROUS RETINOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GYNECOMASTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SUBRETINAL FLUID; TREATMENT OUTCOME; DOSE RESPONSE; DRUG ADMINISTRATION; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; CENTRAL SEROUS CHORIORETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPLERENONE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; SPIRONOLACTONE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84991628014     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-016-0377-2     Document Type: Article

References (26)

1. Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201–214
2. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118
3. Quin G, Liew G, Ho I-V et al (2013) Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol 41:187–200
4. Tittl MK, Spaide RF, Wong D et al (1999) Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 128:63–68
5. Haimovici R, Koh S, Gagnon DR et al (2004) Risk factors for central serous chorioretinopathy: a case–control study. Ophthalmology 111:244–249
6. Bouzas EA, Karadimas P, Pournaras CJ (2002) Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 47(5):431–448
7. Farman N, Rafestin-Oblin ME (2001) Multiple aspects of mineralocorticoid selectivity. Am J Physiol Ren Physiol 280:F181–F192
8. Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Investig 122(7):2672–2679
9. Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny JC, Jaisser F, Farman N, Behar-Cohen F (2010) The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 24(9):3405–3415
10. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33(10):2096–2102
11. Bousquet E, Beydoun T, Rothschild PR, Bergin C, Zhao M, Batista R, Brandely ML, Couraud B, Farman N, Gaudric A, Chast F, Behar-Cohen F (2015) Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina 35(12):2505–2515
12. Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29:1469–1473
13. Carrai P, Pichi F, Bonsignore F, Ciardella AP, Nucci P (2015) Wide-field spectral domain-optical coherence tomography in central serous chorioretinopathy. Int Ophthalmol 35(2):167–171
14. Farman N, Rafestin-Oblin ME (2001) Multiple aspects of mineralocorticoid selectivity. Am J Physiol Ren Physiol 280(2):F181–F192
15. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M (2007) The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal 5:e012
16. Colussi G, Catena C, Sechi LA (2013) Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens 31(1):3–15
17. Struthers A, Krum H, Williams GH (2008) A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 31(4):153–158
18. Danjuma MI, Mukherjee I, Makaronidis J, Osula S (2014) Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep 16(2):414
19. Steinle NC, Gupta N, Yuan A, Singh RP (2012) Oral rifampin utilization for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol 96:10–13
20. Meyerle CB, Freund KB, Bhatnagar P et al (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946
21. Nielsen JS, Jampol LM (2011) Oral mifepristone for chronic central serous chorioretinopathy. Retina 31:1928–1936
22. Forooghian F, Meleth AD, Cukras C et al (2011) Finasteride for chronic central serous chorioretinopathy. Retina 31:766–771
23. Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466
24. Chan W-M, Lai TYY, Lai RYK et al (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765
25. Bae SH (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152(5):784–792
26. Schaal KB, Hoeh AE, Scheuerle A et al (2009) Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol 19:613–617